SunRISe-5 and MoonRISe-1 trials investigate TAR-200 and TAR-210 in non-muscle-invasive bladder cancer, focusing on disease-free survival and recurrence prevention. ARASTEP trial evaluates darolutamide ...

The PRELUDE trial is assessing oncological outcomes with neoadjuvant 177Lu-PSMA-617 in high-risk, localized prostate cancer. 177 Lu-PSMA-617 (Pluvicto) was approved by the FDA in March 2022 for ...

The release of the first overactive bladder (OAB) guidelines was associated with an increase in OAB diagnoses, a decrease in anticholinergic medication use, and a rise in beta-3 agonist use, according ...

Biomarkers are vital in diagnosing and managing urological diseases, with PSA testing crucial for early prostate cancer detection. State legislation is increasingly mandating insurance coverage for ...

UTUC affects 1-2 per 100,000 people in the U.S., representing 6% of urothelial carcinoma cases, with symptoms like hematuria and urinary obstruction. Treatment strategies for UTUC depend on tumor ...

We preview several noteworthy P2 presentations in the urologic oncology space. The American Urological Association (AUA) will try its luck in Las Vegas, Nevada for its 2025 annual meeting. Taking ...

The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey. Receiving an initial diagnosis of renal cell carcinoma (RCC) is often an overwhelming ...

Combination of BWL and ultrasonic propulsion effectively fragments and repositions small renal stones in awake patients without anesthesia. The procedure achieved a 71% success rate in reducing stone ...

A panelist discusses how both the ARCHES and ARANOTE trials demonstrated significant improvements in radiographic progression-free survival with their respective novel hormonal therapies (enzalutamide ...

The use of onabotulinumtoxinA (onabotA, Botox) for the treatment of overactive bladder comes with several important considerations. The use of onabotulinumtoxinA (onabotA, Botox) for the treatment of ...

Panelist discusses how patient outcomes have evolved over time with different benign prostatic hyperplasia (BPH) treatments, highlighting improvements in ejaculation preservation, durability, and post ...

“Like any disease state, you want to make sure you have the right diagnosis; otherwise, you're not going to have a successful treatment plan," says Karyn S. Eilber, MD. The landscape of treatment for ...